Dr. Angèle Maki is a seasoned biopharmaceutical executive with over two decades of deal-making experience across both small biotech and large pharmaceutical companies. She currently serves as Chief Business Officer at Callio Therapeutics, a newly formed biotech company dedicated to unlocking the potential of multi-payload antibody-drug conjugates. Throughout her career, Angèle has held progressively more senior business development roles, starting at Medarex followed by Bristol Myers Squibb (which acquired Medarex), Genentech, Merck & Co., Eli Lilly, ReCode, and Hummingbird Bioscience. She has successfully led due diligence and negotiations for a broad range of in- and out-licensing transactions, spanning early-stage research technologies to clinical-stage assets. Additionally, she played a key role within Lilly’s corporate venture arm, driving strategic investment decisions. Angèle is also the board chair of the non-profit, Canadian Entrepreneurs in Life Sciences. She holds a Ph.D. in Biological Chemistry from Stanford University and a B.Sc. in Chemistry from the University of Winnipeg, Canada.